CliffBio
small molecule

RELISTOR

METHYLNALTREXONE BROMIDE

Loss of exclusivityDecember 2030latest FDA-listed patent expiry
CompanySalix Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand nameRELISTOR
Active ingredientMETHYLNALTREXONE BROMIDE
Strength8MG/0.4ML (8MG/0.4ML)
Dosage formSOLUTION
RouteSUBCUTANEOUS
ModalitySmall molecule
FDA approvalSeptember 2010
Marketing statusRX

Listed patents

PatentExpiresType
8247425December 2030use U-1185
8420663September 2029use U-1185
8822490September 2029product
9180125September 2029product
9492445September 2029product
12303592August 2027product

More from Salix Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

RELISTOR patent cliff — loss of exclusivity December 2030 | CliffBio